rethinkPeptides Search
Menu
Study breakdown

CGRP Affects Inner Ear Electrical Signals and Increases Sensory Sensitivity in Migraine

Animal StudyLow Moderate evidence
The takeaway

Systemic CGRP modifies electrical potentials in the cochlea and vestibular organs while increasing auditory and vestibular hypersensitivity, linking it to migraine sensory symptoms.

18%

of people worldwide affected by migraine, with CGRP now linked to inner ear sensory dysfunction

What the researchers found

Systemic CGRP modifies electrical potentials in both cochlear and vestibular end organs and increases auditory and vestibular sensory hypersensitivities.

Why it matters

Reveals a peripheral mechanism for migraine-associated sensory symptoms, suggesting anti-CGRP drugs may work partly by protecting the inner ear from CGRP-driven hypersensitivity.

The numbers in context

Systemic CGRP modified cochlear and vestibular end organ potentials; increased auditory and vestibular behavioral sensitivities.

How the study worked

Neurophysiology study measuring auditory and vestibular end organ electrical potentials after systemic CGRP administration, with parallel assessment of sensory sensitivity changes.

Who was studied

Mice (strain not specified in abstract)

What this study cannot tell us

Animal study — human inner ear physiology may respond differently; systemic CGRP delivery may not perfectly mimic natural release patterns during migraine; acute study design.

How to read the evidence

Neurophysiology study with direct electrical measurements; provides mechanistic evidence but needs human clinical correlation.

When this study was published

Published in 2025, expanding the understanding of CGRP's role beyond central nervous system migraine pathways.

The bigger picture

Understanding CGRP's peripheral effects on the inner ear adds a new dimension to migraine therapy — anti-CGRP drugs may not only prevent headaches but also directly reduce the sound sensitivity and dizziness that make migraine so disabling.

Questions still open

  • Do anti-CGRP therapies measurably reduce inner ear hypersensitivity in migraine patients?
  • Could targeted inner ear delivery of CGRP antagonists treat vestibular migraine more specifically?

Common questions

Why does migraine cause sound sensitivity and dizziness?
CGRP, a key migraine peptide, signals at nerve endings in the inner ear (both hearing and balance organs). This study shows systemic CGRP alters electrical signals in these organs and increases sensory sensitivity — explaining why migraine sufferers often experience sound sensitivity and dizziness.
Could anti-CGRP drugs help with migraine dizziness?
Yes — by blocking CGRP's effects on the vestibular (balance) and cochlear (hearing) organs, anti-CGRP therapies like erenumab, fremanezumab, and galcanezumab may directly reduce the sensory hypersensitivities that make migraine so disabling.

Read the original research

Systemic calcitonin gene-related peptide modifies auditory and vestibular end organ electrical potentials, and increases sensory hypersensitivities.

Journal of neurophysiology, 134(1), 107-117

Citation

Rahman, Shafaqat M; Faucher, Stefanie; Jonnala, Raajan; Holt, Joseph C; Lee, Choongheon; Luebke, Anne E. (2025). Systemic calcitonin gene-related peptide modifies auditory and vestibular end organ electrical potentials, and increases sensory hypersensitivities.. Journal of neurophysiology, 134(1), 107-117. https://doi.org/10.1152/jn.00226.2024